This study is a single-center, randomized, double-blind, placebo-controlled, dose-increasing phase I clinical study.

The purpose of this study is to evaluate the safety, tolerance, pharmacokinetics and immunogenicity of single and multiple subcutaneous administration of CM326 at different doses in healthy male subjects.

Inclusion Criteria:

• Age ≥18 years and ≤ 65 years, healthy male.
• With normal or abnormal laboratory test results without clinical significanceat screening period and baseline.
• Subjects can communicate well with investigators and comply with protocol requirements.

Exclusion Criteria:

• Any live attenuated vaccine is planned to be inoculated 30 days before administration or during the study period.
• Major surgery is planned during the study period.
• The average daily smoking volume is more than 5 cigarettes within 3 months before screening.
• Within 12 weeks before administration, blood loss from voluntary blood donation or any attempt to visit is greater than 400 mL.
• There are any reasons that the investigator believes will prevent the subject from participating in the study.